Tegaserod maleate (Zelnorm)

Agent for short term treatment of women with irritable bowel syndrome whose primary bowel symptom is constipation.

Removed from market March 2007 for concerns about increased cardiovascular risks and approved in August 2007 for women with irritable bowel syndrome-constipation for women younger than 55 years, without cardiovascular disease and who have not responded to other therapies.

Nonselective serotonin 5-hydroxytryptamine4 (5-HT4).

Leave a Reply

Your email address will not be published. Required fields are marked *